NPF Statement on the Neupro® Patch

Release date: 7/16/2012

NPF Statement on the Neupro® Patch

"We received news that the Rotigotine patch has been re-approved and is now available. Because Parkinson's disease patients typically have to take many doses of medications each day, the re-approval of the patch will hopefully be a boost to some sufferers.  Please consult your neurologist if you are interested in this therapy. Trials of Rotigotine will likely require re-balancing of your medications, and close monitoring for side effects."
— Dr. Michael S. Okun, National Medical Director of the National Parkinson Foundation

Excerpt from the UCB press release:

UCB Launches Neupro® in the U.S. to treat Parkinson’s Disease and Restless Legs Syndrome
July 16, 2012 – UCB announced today that Neupro® (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro® was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome.

Read the full press release from UCB.

Print